Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib …
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib …
NTRK fusion-positive cancers and TRK inhibitor therapy
N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
[HTML][HTML] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 …
Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …
(ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the …
Non-small-cell lung cancers: a heterogeneous set of diseases
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …
[HTML][HTML] Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Background Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …